- AcelRx Pharmaceuticals recently reported their Q1 earnings with EPS coming in line with the Street’s expectations, but they reported a big miss on revenue.
- Despite the miss on revenue, I am feeling bullish about ACRX due to the increase in elective surgeries that should help with DSUVIA’s adoption.
- The company is looking to close an out-licensing deal for DSUVIA before year-end, which should come with a sizeable upfront payment, commercial milestones, and royalties.
- I point out some of the key takeaways from the company’s Q1 report and earnings call. In addition, I share my strategy for adding to ACRX in the near term and how I intend to manage my ACRX for the remainder of 2021.
For further details see:
AcelRx Pharmaceuticals: Moving Closer To An Attractive Risk-Reward